OphtiMed Rx LTD is a preclinical ophthalmic drug development company led by experts in ophthalmology, molecular biology, biotech, out-licensing, and M&As.
The company is developing a novel molecular therapy for dry Age-related Macular Degeneration (AMD), a leading cause of blindness affecting millions worldwide. Yet, no effective treatments exist to prevent retinal damage and vision loss.
Our drug targets the aging process (cellular senescenc...